Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E. Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. Ohno Y, Nakashima J, Ohori M, Hatano T, Tachibana M. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Tumor-infiltrating cd8+ lymphocytes predict clinical outcome in breast cancer. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, et al. Lymphocyte infiltrates as a prognostic variable in female breast cancer. 2012 30:1796–804.Īaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
Von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, et al. Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. Gonzalez-Angulo AM, McGuire SE, Buchholz TA, Tucker SL, Kuerer HM, Rouzier R, et al. Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Kong X, Moran MS, Zhang N, Haffty B, Yang Q.
#SPSS 23 EL CAPITAN TRIAL#
Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. Untch M, Fasching PA, Konecny GE, Hasmuller S, Lebeau A, Kreienberg R, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, et al. The NLR provides additional prognostic information to choose suitable patients who might profit from further therapy. The NLR is an independent prognostic factor for RFS and OS in breast cancer patients with ER/PR-positive and HER2-negative subtype receiving NAC. Uni- and multivariate Cox analysis showed NLR to be an only predictor of RFS and OS. Particularly, high NLR patients had inferior clinical outcomes in the high clinical stage. Subgroup analysis of non-pathologic complete response (pCR) subgroup showed that high NLR was significant for RFS and OS ( P = 0.001 and P < 0.001). On univariate analysis, high NLR (>2.25) correlated with poorer recurrence-free survival (RFS) and overall survival (OS) ( P = 0.001 and P < 0.001). The median follow-up after surgery was 21 months (range, 1–108 months). We performed retrospective analysis of 157 patients with primary breast cancer with ER/PR-positive and HER2-negative subtype who were treated with NAC, followed by definitive surgical resection. The aim of this study was to determine the predictive or prognostic impact of absolute neutrophil count/absolute lymphocyte count ratio (NLR) in breast cancer patients with estrogen receptor/progesterone receptor (ER/PR)-positive and human epidermal growth factor receptor 2 (HER2)-negative subtype who have received neoadjuvant chemotherapy (NAC).
0 kommentar(er)
